Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Does the patient with myelofibrosis feel better through pacritinib?

EHA 2015

11 - 14 Jun 2015

Published: 12 Jun 2015

Views: 2136

Rating:

Save

Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA

At a press conference at EHA 2015, Dr Mesa presented new data from the Phase 3 PERSIST-1 study which showed that pacritinib is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis.

Read the news story for more.

Related Videos

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Choosing the right patients for transplant

Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Choosing the right patients for transplant ( Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India )

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL...

Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation ( Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy )

Encouraging results using mismatched unrelated donors in stem cell...

Dr Monzr Al Malki and Dr Steven Devine

Encouraging results using mismatched unrelated donors in stem cell transplantation ( Dr Monzr Al Malki and Dr Steven Devine )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible...

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Linvoseltamab induces deep and durable responses in patients with relapsed or...

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA

$Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )$

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...

Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )

More from ecancer